CytoMed Therapeutics Ltd Dossier - Source-backed chat

CytoMed Therapeutics Ltd

GDTCNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.37

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.90Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $10.7M

Enterprise Value $9.4M

Shares Outstanding 11.6M diluted

Next Earnings Date31 Mar 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

CytoMed Therapeutics is a clinical-stage biopharmaceutical company pioneering off-the-shelf, donor-derived gamma delta T cell and NK cell immunotherapies. While its proprietary platforms (such as CTM-N2D and CTM-GDT) target significant unmet needs in solid and hematological tumors, the company is in its operational infancy with minimal commercial revenues (primarily from its newly acquired Malaysian cord blood banking assets). Given its high cash burn relative to its limited cash reserves of $1.63M USD as of December 31, 2025, the company faces substantial going-concern risks. A 'Hold' rating is recommended until the company secures long-term financing or demonstrates robust clinical efficacy data from its ongoing Phase I ANGELICA trial.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company experiences clinical trial delays or safety concerns (e.g., dose-limiting toxicities) in the ANGELICA trial. Concurrently, the company is unable to raise sufficient capital through its ATM program or real estate monetization, leading to severe liquidity constraints and dilution of existing shareholders.

Base CaseCentral scenario

The company successfully completes Phase I dose escalation for its lead candidate CTM-N2D in Singapore and initiates its Phase I trial for unmodified CTM-GDT in Malaysia. Capital runway is extended incrementally through its ATM program and non-dilutive grants, keeping the company operational but highly sensitive to capital market conditions.

Bull CaseUpside scenario

CytoMed's proprietary 'off-the-shelf' allogeneic gamma delta T cell and iPSC-derived gdNKT platforms offer a highly scalable, cost-effective alternative to patient-specific autologous CAR-T therapies. By utilizing healthy donor blood and cord blood assets integrated via its LongevityBank subsidiary, the company bypasses complex donor-patient matching and high manufacturing costs. This cost-efficient Southeast Asian infrastructure, combined with strategic clinical trials in Singapore and Malaysia, positions CytoMed to capture a significant share of the global oncology and regenerative medicine markets.

Scenarios reflect our research view at the research date.

Key Investment Merits

Proprietary, off-the-shelf allogeneic gamma delta T cell platform that does not require expensive patient-specific genetic modification.
Active Phase I clinical trial (ANGELICA) in Singapore with established clinical infrastructure and collaboration with National University Hospital.
Diversified pipeline including cord blood-derived Natural Killer (NK) cells supported by Singapore government agency Enterprise Singapore.
Asset-backed flexibility with ownership of 5 production properties across Singapore and Malaysia available for potential monetization.

Key Investment Risks

Going concern risk with only $1.63M USD in cash and bank balances as of December 31, 2025, against an annual net loss of $3.11M USD.
High risk of shareholder dilution due to reliance on the active $4.3M USD At-The-Market (ATM) equity offering program.
Early-stage clinical pipeline with no approved products and no guarantee of clinical efficacy or regulatory approval.
Extremely low trading volume and micro-cap status, leading to high stock price volatility.

Thesis Invalidation Triggers

Failure to submit or obtain approval for the CTM-GDT IND application in Malaysia.
Severe adverse safety events or dose-limiting toxicities observed during the ANGELICA trial.
Inability to secure additional funding or strategic partnerships before cash reserves are fully depleted.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.